0.75 CEUs
Safety Surveillance Through Antiretroviral Pregnancy Registry
Course Description
This activity has been designed to meet the educational needs of physicians, physician assistants, nurse practitioners, pharmacists, and registered nurses; other healthcare providers, such as nutritionists, social workers, and case managers are also encouraged to attend.
Credit Dates May 20, 2022 - May 20, 2023
Estimated time to complete activity: 0.75 hours
This activity is jointly provided by the American Academy of HIV Medicine in collaboration with Postgraduate Institute for Medicine.
This activity is supported by independent educational grants from Gilead Sciences, Janssen Therapeutics, and ViiV Healthcare.
Credit Dates May 20, 2022 - May 20, 2023
Estimated time to complete activity: 0.75 hours
This activity is jointly provided by the American Academy of HIV Medicine in collaboration with Postgraduate Institute for Medicine.
This activity is supported by independent educational grants from Gilead Sciences, Janssen Therapeutics, and ViiV Healthcare.
Educational Objectives
After completing this activity, the participant should be better able to:
After completing this activity, the participant should be better able to:
- Describe the objectives of the Antiretroviral Pregnancy Registry (APR)
- List key findings from analysis of APR data
- Describe four steps to report a drug exposure to the APR
- Identify early warning signals of major tetrogenicity
Target Audience
This activity has been designed to meet the educational needs of physicians, physician assistants, nurse practitioners, pharmacists, and registered nurses; other healthcare providers, such as nutritionists, social workers, and case managers are also encouraged to attend.
Faculty
William Short, MD, MPH, FIDSA, AAHIVS
Associate Professor
Perleman School of Medicine
University of Pennsylvania
Lynne M. Mofenson, MD
Senior HIV Technical Advisory
Elizabeth Glaser Pediatric AIDS Foundation
Angela Scheuerle, MD, FAAP, FACMG
Professor, Department of Pediatrics, Division of Genetic and Metabolism Director, UTSW Rare Disease Center of Excellence University of Texas Southwestern Medical
Jessica Albano, PhD, MPH
Vice President, Epidemiology and Analytics
Syneos Health
Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period May 20, 2022 through May 20, 2023 participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 16798. Upon registering and completing the activity evaluation, your certificate will be made available immediately.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The American Academy of HIV Medicine. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Continuing Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.75 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number JA4008162-9999-22-286-H02-P)
Type of Activity: Knowledge
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours. Designated for 0.75 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This activity has been designed to meet the educational needs of physicians, physician assistants, nurse practitioners, pharmacists, and registered nurses; other healthcare providers, such as nutritionists, social workers, and case managers are also encouraged to attend.
Faculty
William Short, MD, MPH, FIDSA, AAHIVS
Associate Professor
Perleman School of Medicine
University of Pennsylvania
Lynne M. Mofenson, MD
Senior HIV Technical Advisory
Elizabeth Glaser Pediatric AIDS Foundation
Angela Scheuerle, MD, FAAP, FACMG
Professor, Department of Pediatrics, Division of Genetic and Metabolism Director, UTSW Rare Disease Center of Excellence University of Texas Southwestern Medical
Jessica Albano, PhD, MPH
Vice President, Epidemiology and Analytics
Syneos Health
Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period May 20, 2022 through May 20, 2023 participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 16798. Upon registering and completing the activity evaluation, your certificate will be made available immediately.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The American Academy of HIV Medicine. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.Physician Continuing Medical Education
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Continuing Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.75 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number JA4008162-9999-22-286-H02-P)
Type of Activity: Knowledge
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours. Designated for 0.75 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
